A personalized approach to medical rehabilitation for patients with rhinosinusitis with nasal polyps and comorbid asthma

Abstract

BACKGROUND: Personalized medical rehabilitation options are required for patients with chronic rhinosinusitis with nasal polyps owning to the relatively high prevalence of this disease, its long and often uncontrolled course, and the significant decrease in quality of life of patients. Comorbid asthma is common in patients with rhinosinusitis with nasal polyps and is associated with more severe clinical manifestations and increased unresponsiveness to therapy, reducing the effectiveness of rehabilitation efforts.

AIM: The aim of the study was to identify predictors of personalized comprehensive rehabilitation options to be used in patients with rhinosinusitis with nasal polyps and comorbid asthma in order to achieve greater clinical effectiveness of therapy and control of nasal polyps.

MATERIALS AND METHODS: The study was conducted in 35 patients with rhinosinusitis with nasal polyps and comorbid asthma. Comprehensive medical rehabilitation included endonasal use of Nasonex 2 doses twice daily; nasal rinsing twice daily; subcutaneous use of dupilumab at 300 µg every 2 weeks; use of low-dose inhaled corticosteroid (beclomethasone dipropionate at 200 µg twice daily); a course of alternating magnetic field therapy, low-intensity laser radiation, and interval hypoxic training. At baseline, nasal polyp severity, respiratory function, quality of life, and levels of cytokines, immunoglobulins, leukocytes, lymphocytes, and eosinophils were assessed. The effectiveness of rehabilitation measures was assessed 6 months after the start of treatment using the International Classification of Functioning, Disability, and Health criteria.

RESULTS: Using multiple regression analysis, an information model was developed to predict effectiveness of comprehensive medical rehabilitation in patients with rhinosinusitis with nasal polyps and comorbid asthma. The resulting attribute of the model was the final score of the seven selected domains of the International Classification of Functioning, Disability, and Health. A cluster of baseline clinical and laboratory variables was identified as predictors, including blood eosinophil level, blood tumor necrosis factor-alpha (TNF-alpha) level, total score for a 22-item Sino-Nasal Outcome Test (SNOT-22) functional domain, and forced expiratory volume in one second. Higher level of rehabilitation was achieved with the following baseline characteristics: blood eosinophil counts no more than 0.85 × 10⁹/L; blood TNF-α level no more than 18.0 pg/mL; total score for the SNOT-22 functional domain no more than 8; forced expiratory volume in one second no less than 2.6 L.

CONCLUSION: At baseline, the identified thresholds of the selected predictors predict the outcome that could be achieved for each patient who receives personalized comprehensive rehabilitation.

Keywords

asthma / interval hypoxic training / medical rehabilitation / low-intensity laser radiation / alternating magnetic field therapy / personalized healthcare / rhinosinusitis with nasal polyps / predictors

References

[1] Eskofier BM, Klucken J. Predictive models for health deterioration: Understanding disease pathways for personalized medicine. Annu Rev Biomed Eng. 2023;25(1):131–156. EDN: SWSUTE doi: 10.1146/annurev-bioeng-110220-030247

[2] Eskofier B.M., Klucken J. Predictive models for health deterioration: Understanding disease pathways for personalized medicine // Annu Rev Biomed Eng. 2023. Vol. 25, N 1. P. 131–156. EDN: SWSUTE doi: 10.1146/annurev-bioeng-110220-030247

[3] Moreira AG, Kamat D. Personalized medicine. Pediatr Ann. 2022;51(10):e379–e380. doi: 10.3928/19382359-20220803-02

[4] Moreira A.G., Kamat D. Personalized medicine // Pediatr Ann. 2022. Vol. 51, N 10. P. e379–e380. doi: 10.3928/19382359-20220803-02

[5] Benkov AA, Nagornev SN, Mamedova SS, Shabanova AS. Predictors of effectiveness in the implementation of personalized use of therapeutic physical factors in patients with metabolic syndrome. Fizioterapiya, bal’neologiya i reabilitatsiya = Russ J Physical Ther Balneother Rehabilitat. 2022;21(6):437–445. EDN: VLTKVZ doi: 10.17816/rjpbr352577

[6] Беньков А.А., Нагорнев С.Н., Мамедова С.С., Шабанова А.Ш. Предикторы эффективности в реализации персонифицированного применения лечебных физических факторов у больных метаболическим синдромом // Физиотерапия, бальнеология, реабилитация. 2022. Т. 21, № 6. С. 437–445. EDN: VLTKVZ doi: 10.17816/rjpbr352577

[7] Van der Wouden CH, Böhringer S, Cecchin E, et al. Generating evidence for precision medicine: Considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenet Genomics. 2020;30(6):131–144. EDN: ZNYHNG doi: 10.1097/FPC.0000000000000405

[8] Van der Wouden C.H., Böhringer S., Cecchin E., et al. Generating evidence for precision medicine: Considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study // Pharmacogenet Genomics. 2020. Vol. 30, N 6. P. 131–144. EDN: ZNYHNG doi: 10.1097/FPC.0000000000000405

[9] Cecchin E, Stocco G. Pharmacogenomics and personalized medicine. Genes (Basel). 2020;11(6):679.doi: 10.3390/genes11060679

[10] Cecchin E., Stocco G. Pharmacogenomics and personalized medicine // Genes (Basel). 2020. Vol. 11, N 6. P. 679. doi: 10.3390/genes11060679

[11] Mauriello A, Ascrizzi A, Molinari R, et al. Pharmacogenomics of cardiovascular drugs for atherothrombotic, thromboembolic and atherosclerotic risk. Genes (Basel). 2023;14(11):2057. EDN: SMVJGI doi: 10.3390/genes14112057

[12] Mauriello A., Ascrizzi A., Molinari R., et al. Pharmacogenomics of cardiovascular drugs for atherothrombotic, thromboembolic and atherosclerotic risk // Genes (Basel). 2023. Vol. 14, N 11. P. 2057. EDN: SMVJGI doi: 10.3390/genes14112057

[13] Vuic B, Milos T, Tudor L, et al. Pharmacogenomics of dementia: Personalizing the treatment of cognitive and neuropsychiatric symptoms. Genes (Basel). 2023;14(11):2048. EDN: EWMJWQ doi: 10.3390/genes14112048

[14] Vuic B., Milos T., Tudor L., et al. Pharmacogenomics of dementia: Personalizing the treatment of cognitive and neuropsychiatric symptoms // Genes (Basel). 2023. Vol. 14, N 11. P. 2048. EDN: EWMJWQ doi: 10.3390/genes14112048

[15] Gambale E, Boddi A, Pasqui A, et al. Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity. Cancer Treat Res Commun. 2022;31:100528. EDN: IREOWV doi: 10.1016/j.ctarc.2022.100528

[16] Gambale E., Boddi A., Pasqui A., et al. Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity // Cancer Treat Res Commun. 2022. Vol. 31. P. 100528. EDN: IREOWV doi: 10.1016/j.ctarc.2022.100528

[17] Ponomarenko GN. The concept of translational medicine in physiotherapy and rehabilitation. Fizioterapiya, bal’neologiya i reabilitatsiya = Russ J Physical Ther Balneother Rehabilitat. 2014;(3):4–12. EDN: QHXAID

[18] Пономаренко Г.Н. Концепция трансляционной медицины в физиотерапии и реабилитации // Физиотерапия, бальнеология и реабилитация. 2014. № 3. С. 4–12. EDN: QHXAID

[19] Krysyuk OB, Obrezan AG, Ponomarenko GN. The problems of personalized vtdicine in therapeutical practice. Vestnik Saint-Petersburg univer. Medicine. 2006;(1):16–22. EDN: RTSKAF

[20] Крысюк О.Б., Обрезан А.Г., Пономаренко Г.Н. Проблемы персонифицированной медицины в клинике внутренних болезней // Вестник Санкт-Петербургского университета. Медицина. 2006. № 1. С. 16–22. EDN: RTSKAF

[21] Chen XQ, Sawa M, Mobley WC. Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome. Free Radic Biol Med. 2018;114:52–61. EDN: YDIJPN doi: 10.1016/j.freeradbiomed.2017.10.341

[22] Chen X.Q., Sawa M., Mobley W.C. Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome // Free Radic Biol Med. 2018. Vol. 114. Р. 52–61. EDN: YDIJPN doi: 10.1016/j.freeradbiomed.2017.10.341

[23] Jacob M, Lopata AL, Dasouki M, et al. Metabolomics toward personalized medicine. Mass Spectrom Rev. 2019;38(3):221–238. doi: 10.1002/mas.21548

[24] Jacob M., Lopata A.L., Dasouki M., et al. Metabolomics toward personalized medicine // Mass Spectrom Rev. 2019. Vol. 38, N 3. Р. 221–238. doi: 10.1002/mas.21548

[25] Luchinin AS, Lyanguzov AV. Feature selection for medical prognostic models. Vrach i informacionnye tehnologii = Medical Doctor Information Technologies. 2022;(3):54–67. EDN: RCABBS doi: 10.25881/18110193_2022_3_54

[26] Лучинин А.С., Лянгузов А.В. Выбор предикторов для моделей классификации и прогноза в медицине // Врач и информационные технологии. 2022. № 3. С. 54–67. EDN: RCABBS doi: 10.25881/18110193_2022_3_54

[27] Kuznetsova EV, Zhuravleva MV, Mikhailov IA, Kurnosova TI. Development of methodological approaches to the formation of a risk-based model to minimize the prevalence of adverse reactions in drug application in medical organizations of Moscow. Farmakoekonomika: Modern Pharmacoeconom Pharmacoepidemiol. 2023;16(2):248–257. EDN: QZZHKX doi: 10.17749/2070-4909/farmakoekonomika.2023.184

[28] Кузнецова Е.В., Журавлева М.В., Михайлов И.А., и др. Разработка методических подходов к формированию риск-ориентированной модели для минимизации возникновения нежелательных реакций при применении лекарственных препаратов в медицинских организациях города Москвы // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2023. Т. 16, № 2. С. 248–257. EDN: QZZHKX doi: 10.17749/2070-4909/farmakoekonomika.2023.184

[29] Kuznetsova NO. Determination of diastolic dysfunction of the left ventricle by means of ECG spectral analysis with the help of a single-channel ECG monitor [dissertation abstract]: 3.1.20. Place of defence: The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation. Moscow; 2022. 110 р. (In Russ.) EDN: ONDURN

[30] Кузнецова Н.О. Определение диастолической дисфункции левого желудочка посредством спектрального анализа ЭКГ с помощью одноканального ЭКГ монитора: Дис. ... канд. мед. наук: 3.1.20. Место защиты: Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России. Москва, 2022. 110 с. EDN: ONDURN

[31] Shamkina PA, Krivopalov AA, Ryazantsev SV, et al. Epidemiology of chronic rhinosinusitis. Sovremennye problemy nauki i obrazovaniya. 2019;(3):188–206. EDN: SQILCY

[32] Шамкина П.А., Кривопалов А.А., Рязанцев С.В., и др. Эпидемиология хронических риносинуситов // Современные проблемы науки и образования. 2019. № 3. С. 188–206. EDN: SQILCY

[33] Mullol J, Azar A, Buchheit KM, et al. Chronic rhinosinusitis with nasal polyps: Quality of life in the biologics era. J Allergy Clin Immunol Pract. 2022;10(6):1434–1453.e9. EDN: TOGQCB doi: 10.1016/j.jaip.2022.03.002

[34] Mullol J., Azar A., Buchheit K.M., et al. Chronic rhinosinusitis with nasal polyps: Quality of life in the biologics era // J Allergy Clin Immunol Pract. 2022. Vol. 10, N 6. P. 1434–1453.e9. EDN: TOGQCB doi: 10.1016/j.jaip.2022.03.002

[35] Pelaia C, Pelaia G, Maglio A, et al. Pathobiology of type 2 inflammation in asthma and nasal polyposis. J Clin Med. 2023;12(10):3371. EDN: SXSAGI doi: 10.3390/jcm12103371

[36] Pelaia C., Pelaia G., Maglio A., et al. Pathobiology of type 2 inflammation in asthma and nasal polyposis // J Clin Med. 2023. Vol. 12, N 10. P. 3371. EDN: SXSAGI doi: 10.3390/jcm12103371

[37] Striz I, Golebski K, Strizova Z, et al. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clin Sci (Lond). 2023;137(9):727–753. doi: 10.1042/CS20190281

[38] Striz I., Golebski K., Strizova Z., et al. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis // Clin Sci (Lond). 2023. Vol. 137, N 9. P. 727–753. doi: 10.1042/CS20190281

[39] Beregansky PV, Melnikova IM, Misernitsky YL. Significance mikrocirkulatory disorders in the pathogenesis of respiratory allergy. Vestnik Surgutskogo gosudarstvennogo universiteta. Medicina. 2012;(3):6–14. EDN: RZDOIR

[40] Бережанский П.В., Мельникова И.М., Мизерницкий Ю.Л. Значение микроциркуляторных нарушений в патогенезе респираторной аллергии // Вестник СурГУ. Медицина. 2012. № 3. С. 6–14. EDN: RZDOIR

[41] Korkmazov MY, Kazachkov EL, Lengina MA, et al. Cause-effect factors of rhinosinusitis poliposa development. Rossiyskaya Rinologia = Russ Rhinol. 2023;31(2):124–130. EDN: HHXGVS doi: 10.17116/rosrino202331021124

[42] Коркмазов М.Ю., Казачков Е.Л., Ленгина М.А., и др. Причинно-следственные факторы развития полипозного риносинусита // Российская ринология. 2023. Т. 31, № 2. С. 124–130. EDN: HHXGVS doi: 10.17116/rosrino202331021124

[43] Shishkin AA, Karakulova YV. Vegetative disorders and serotonin of blood serum in the case of chronic rhinosinusitis polyposa. Med Almanac. 2017;(5):108–110. EDN: ZSBPXR

[44] Шишкин А.А., Каракулова Ю.В. Вегетативные нарушения и серотонин сыворотки крови при хроническом полипозном риносинусите // Медицинский альманах. 2017. № 5. С. 108–110. EDN: ZSBPXR

[45] Nellis JC, Payne SC. Paroxysmal autonomic dysfunction in a patient with chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2014;150(1):157–159. doi: 10.1177/0194599813509060

[46] Nellis J.C., Payne S.C. Paroxysmal autonomic dysfunction in a patient with chronic rhinosinusitis // Otolaryngol Head Neck Surg. 2014. Vol. 150, N 1. P. 157–159. doi: 10.1177/0194599813509060

[47] Popov IB, Shcherbakov DA, Tyryk OB, Aleksanyan TA. New approach to treatment of polypous rhinosinusitis. Vestnik otorinolaringologii = Bull Otorhinolaryngol. 2020;85(3):48–51. EDN: ZCVCMN doi: 10.17116/otorino20208503148

[48] Попов И.Б., Щербаков Д.А., Тырык О.Б., Алексанян Т.А. Новый взгляд на лечение полипозного риносинусита // Вестник оториноларингологии. 2020. Т. 85, № 3. С. 48–51. EDN: ZCVCMN doi: 10.17116/otorino20208503148

[49] Polunina OS, Voronina LP, Sevostyanova IV. The role of oxidative stress in development of endothelial dysfunction at bronchial asthma. Kuban Sci Med Bulletin = Kubanskij nauchnyj medicinskij vestnik. 2011;(5):127–131. EDN: OOZDDF

[50] Полунина О.С., Воронина Л.П., Севостьянова И.В. Роль оксидативного стресса в развитии дисфункции эндотелия при бронхиальной астме // Кубанский научный медицинский вестник. 2011. № 5. С. 127–131. EDN: OOZDDF

[51] Laidlaw TM, Mullol J, Woessner KM, et al. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133–1141. EDN: EHGDWY doi: 10.1016/j.jaip.2020.09.063

[52] Laidlaw T.M., Mullol J., Woessner K.M., et al. Chronic rhinosinusitis with nasal polyps and asthma // J Allergy Clin Immunol Pract. 2021. Vol. 9, N 3. Р. 1133–1141. EDN: EHGDWY doi: 10.1016/j.jaip.2020.09.063

[53] Nagornev SN, Pelishenko TG, Kruglova LS. Assessment of the efficacy of comprehensive medical rehabilitation of patients with polypoid rhinosinusitis based on the international classification of functioning, disability and health. Fiziotherapeutist = Physiotherapist. 2024;20(2):62–73. EDN: UTNNBH doi: 10.33920/med-14-2402-07

[54] Нагорнев С.Н., Пелишенко Т.Г., Круглова Л.С. Оценка эффективности комплексной медицинской реабилитации пациентов с полипозным риносинуситом на основе Международной классификации функционирования, ограничения жизнедеятельности и здоровья // Физиотерапевт. 2024. Т. 20, № 2. С. 62–73. EDN: UTNNBH doi: 10.33920/med-14-2402-07

[55] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. EDN: THMJZZ doi: 10.4193/Rhin20.600

[56] Fokkens W.J., Lund V.J., Hopkins C., et al. European position paper on rhinosinusitis and nasal polyps 2020 // Rhinology. 2020. Vol. 58, Suppl. 29. P. 1–464. EDN: THMJZZ doi: 10.4193/Rhin20.600

[57] Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021;147(1):29–36. EDN: KNJTUD doi: 10.1016/j.jaci.2020.11.013

[58] Bachert C., Han J.K., Wagenmann M., et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management // J Allergy Clin Immunol. 2021. Vol. 147, N 1. P. 29–36. EDN: KNJTUD doi: 10.1016/j.jaci.2020.11.013

[59] Bronchial asthma. Clinical recommendations. Moscow; 2021. 118 р. (In Russ.)

[60] Бронхиальная астма. Клинические рекомендации. Москва, 2021. 118 с.

[61] Dzgoeva IV, Remizova AA. Evaluation of the efficiency of the use of a low-intensity infrared laser and normobaric hypoxia with chronic generalized periodontitis in the long-term period of observations. Russ J Rehab Med. 2021;(3):64–76. EDN: THHYPA

[62] Дзгоева И.В., Ремизова А.А. Оценка эффективности применения низкоинтенсивного инфракрасного лазера и нормобарической гипоксии при хроническом генерализованном пародонтите в отдаленном периоде наблюдений // Russ J Rehab Med. 2021. № 3. С. 64–76. EDN: THHYPA

[63] Braid J, Islam L, Gugiu C, et al. Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps. World Allergy Organ J. 2023;16(5):100776. EDN: CXAMWQ doi: 10.1016/j.waojou.2023.100776

[64] Braid J., Islam L., Gugiu C., et al. Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps // World Allergy Organ J. 2023. Vol. 16, N 5. P. 100776. EDN: CXAMWQ doi: 10.1016/j.waojou.2023.100776

[65] Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis initiative. Rhinosinusitis: Developing guidance for clinical trials. J Allergy Clin Immunol. 2006;118(5 Suppl):S17–61. doi: 10.1016/j.jaci.2006.09.005

[66] Meltzer E.O., Hamilos D.L., Hadley J.A., et al. Rhinosinusitis initiative. Rhinosinusitis: Developing guidance for clinical trials // J Allergy Clin Immunol. 2006. Vol. 118, N 5, Suppl. P. S17–61. doi: 10.1016/j.jaci.2006.09.005

[67] Elishenko TG, Kruglova LS, Nagornev SN. Complex application of healing physical factors in the behavior of medical rehabilitation of patients with polypous rhinosinusitis associated with. Russ J Environmental Rehab Med. 2023;(4):32–39. EDN: ZSEWCW

[68] Пелишенко Т.Г., Круглова Л.С., Нагорнев С.Н. Комплексное применение лечебных физических факторов при поведении медицинской реабилитации пациентов с полипозным риносинуситом, ассоциированным с бронхиальной астмой // Russ J Environmental Rehab Med. 2023. № 4. С. 32–39. EDN: ZSEWCW

[69] Khan AH, Reaney M, Guillemin I, et al. Development of Sinonasal Outcome Test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps. Laryngoscope. 2022;132(5):933–941. EDN: OBOASY doi: 10.1002/lary.29766

[70] Khan A.H., Reaney M., Guillemin I., et al. Development of Sinonasal Outcome Test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps // Laryngoscope. 2022. Vol. 132, N 5. P. 933–941. EDN: OBOASY doi: 10.1002/lary.29766

[71] Pelishenko TG, Kruglova LS, Nagornev SN. Assessing efficacy of comprehensive medical rehabilitation of patients with polypoid rhinosinusitis on the basis of correlation adaptometry method. Fiziotherapeutist = Physiotherapist. 2024;(1):60–70. EDN: HUUYDI doi: 10.33920/med-14-2401-07

[72] Пелишенко Т.Г., Круглова Л.С., Нагорнев С.Н. Оценка эффективности проведения комплексной медицинской реабилитации пациентов с полипозным риносинуситом на основе метода корреляционной адаптометрии // Физиотерапевт. 2024. № 1. С. 60–70. EDN: HUUYDI doi: 10.33920/med-14-2401-07

[73] Burmenskaya AN. Systematic review the international classification of functioning, disability and health in russian-language publications. Domestic J Social Work. 2023;(3):180–187. EDN: VUEJGE

[74] Бурменская А.Н. Обзор исследований в части международной классификации функционирования, ограничений жизнедеятельности и здоровья в русскоязычных публикациях // Отечественный журнал социальной работы. 2023. № 3. С. 180–187. EDN: VUEJGE

[75] Shoshmin AV, Ponomarenko GN. ICF in rehabilitation. 2nd revised and updated. Saint Petersburg; 2020. 232 р. (In Russ.) EDN: UTPVBZ

[76] Шошмин А.В., Пономаренко Г.Н. МКФ в реабилитации. Изд. 2-е, перераб. и доп. Санкт-Петербург, 2020. 232 с. EDN: UTPVBZ

[77] Chalganova AA. Construction of multiple regression and assessment of model quality using Excel spreadsheet processor. Textbook for the discipline ‘Econometrics’. Saint Petersburg: Russian State Hydrometeorological University; 2022. 90 р. (In Russ.) EDN: BVEKEO

[78] Чалганова А.А. Построение множественной регрессии и оценка качества модели с использованием табличного процессора Excel. Учебное пособие по дисциплине «Эконометрика». Санкт-Петербург: Российский государственный гидрометеорологический университет, 2022. 90 с. EDN: BVEKEO

[79] Gevaert P, Han JK, Smith SG, et al. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022;12(11):1413–1423. EDN: ADRMCU doi: 10.1002/alr.22994

[80] Gevaert P., Han J.K., Smith S.G., et al. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps // Int Forum Allergy Rhinol. 2022. Vol. 12, N 11. P. 1413–1423. EDN: ADRMCU doi: 10.1002/alr.22994

[81] Rosati D, Rosato C, Pagliuca G, et al. Predictive markers of long-term recurrence in chronic rhinosinusitis with nasal polyps. Am J Otolaryngol. 2020;41(1):102286. doi: 10.1016/j.amjoto.2019.102286

[82] Rosati D., Rosato C., Pagliuca G., et al. Predictive markers of long-term recurrence in chronic rhinosinusitis with nasal polyps // Am J Otolaryngol. 2020. Vol. 41, N 1. P. 102286. doi: 10.1016/j.amjoto.2019.102286

[83] Corren J, Pham TH, Garcia Gil E, et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022;77(6):1786–1796. doi: 10.1111/all.15197

[84] Corren J., Pham T.H., Garcia Gil E., et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma // Allergy. 2022. Vol. 77, N 6. P. 1786–1796. doi: 10.1111/all.15197

[85] Fitzgerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: Pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64. doi: 10.1016/S2213-2600(17)30344-2

[86] Fitzgerald J.M., Bleecker E.R., Menzies-Gow A., et al. Predictors of enhanced response with benralizumab for patients with severe asthma: Pooled analysis of the SIROCCO and CALIMA studies // Lancet Respir Med. 2018. Vol. 6, N 1. P. 51–64. doi: 10.1016/S2213-2600(17)30344-2

[87] Qing X, Zhang Y, Peng Y, et al. Mir-142-3p regulates inflammatory response by contributing to increased TNF-α in chronic rhinosinusitis with nasal polyposis. Ear Nose Throat J. 2021;100(1):NP50–NP56. doi: 10.1177/0145561319847972

[88] Qing X., Zhang Y., Peng Y., et al. Mir-142-3p regulates inflammatory response by contributing to increased TNF-α in chronic rhinosinusitis with nasal polyposis // Ear Nose Throat J. 2021. Vol. 100, N 1. P. NP50–NP56. doi: 10.1177/0145561319847972

[89] Li L, Zhang Y, Liu H, et al. Exploring causal relationships between inflammatory cytokines and allergic rhinitis, chronic rhinosinusitis, and nasal polyps: A Mendelian randomization study. Front Immunol. 2023;(14):1288517. doi: 10.3389/fimmu.2023.1288517

[90] Li L., Zhang Y., Liu H., et al. Exploring causal relationships between inflammatory cytokines and allergic rhinitis, chronic rhinosinusitis, and nasal polyps: A Mendelian randomization study // Front Immunol. 2023. Vol. 14. P. 1288517. doi: 10.3389/fimmu.2023.1288517

[91] Habib N, Pasha MA, Tang DD. Current understanding of asthma pathogenesis and biomarkers. Cells. 2022;11(17):2764. doi: 10.3390/cells11172764

[92] Habib N., Pasha M.A., Tang D.D. Current understanding of asthma pathogenesis and biomarkers // Cells. 2022. Vol. 11, N 17. P. 2764. doi: 10.3390/cells11172764

[93] Choi JP, Kim YS, Kim OY, et al. TNF-alpha is a key mediator in the development of Th2 cell response to inhaled allergens induced by a viral PAMP double-stranded RNA. Allergy. 2012;67(9):1138–1148. doi: 10.1111/j.1398-9995.2012.02871.x

[94] Choi J.P., Kim Y.S., Kim O.Y., et al. TNF-alpha is a key mediator in the development of Th2 cell response to inhaled allergens induced by a viral PAMP double-stranded RNA // Allergy. 2012. Vol. 67, N 9. P. 1138–1148. doi: 10.1111/j.1398-9995.2012.02871.x

[95] Sieck GC, Dogan M, Young-Soo H, et al. Mechanisms underlying TNFα-induced enhancement of force generation in airway smooth muscle. Physiol Rep. 2019;7(17):e14220. doi: 10.14814/phy2.14220

[96] Sieck G.C., Dogan M., Young-Soo H., et al. Mechanisms underlying TNFα-induced enhancement of force generation in airway smooth muscle // Physiol Rep. 2019. Vol. 7, N 17. P. e14220. doi: 10.14814/phy2.14220

[97] Huang C, Izmailova ES, Jackson N, et al. Remote FEV1 monitoring in asthma patients: A pilot study. Clin Transl Sci. 2021;14(2):529–535. doi: 10.1111/cts.12901

[98] Huang C., Izmailova E.S., Jackson N., et al. Remote FEV1 monitoring in asthma patients: A pilot study // Clin Transl Sci. 2021. Vol. 14, N 2. P. 529–535. doi: 10.1111/cts.12901

[99] Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997–1009. doi: 10.1172/JCI95693

[100] Dunican E.M., Elicker B.M., Gierada D.S., et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction // J Clin Invest. 2018. Vol. 128, N 3. P. 997–1009. doi: 10.1172/JCI95693

[101] Sakai N, Koya T, Murai Y, et al. Effect of benralizumab on mucus plugs in severe eosinophilic asthma. Int Arch Allergy Immunol. 2023;184(8):783–791. doi: 10.1159/000530392

[102] Sakai N., Koya T., Murai Y., et al. Effect of benralizumab on mucus plugs in severe eosinophilic asthma // Int Arch Allergy Immunol. 2023. Vol. 184, N 8. P. 783–791. doi: 10.1159/000530392

RIGHTS & PERMISSIONS

Eco-Vector